INGN — Inogen Inc

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1294133 ·
Last close
$6.54
Market Cap
$177.07M
52W High
$7.67
52W Low
$5.88
ADV30
300,487
Next earnings
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Rove 6 concentrator; Inogen Voxi 5, a stationary oxygen concentrator; Aurora for continuous positive airway pressure; CPAP masks; Simeox for airway clearance treatment; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Beverly, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 85,109,000 37,863,000 -9,336,000 -8,324,000 285,926,000 93,112,000 103,020,000
Dec 2025 81,721,000 35,236,000 -9,306,000 -7,127,000 298,625,000 103,729,000 106,394,000
Sep 2025 92,390,000 41,316,000 -7,116,000 -5,294,000 307,009,000 106,476,000 109,834,000
Jun 2025 92,277,000 41,341,000 -6,129,000 -4,152,000 312,040,000 103,685,000 112,549,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-11,216,000
Investing CF
$-26,209,000
Financing CF
$24,182,000
CapEx
$-10,383,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.86
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-175,584,000
Inventory
$25,969,000
Receivables
$38,863,000
ST Investments
$15,848,000
EBIT TTM
$-30,207,000
Pretax Income TTM
$-23,379,000
Interest Exp TTM
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$351,496,992
EBITDA
$-8,812,000
Free Cash Flow
$-2,406,250
Enterprise Value
$83,560,592
Total Cash
$110,171,000
Total Debt
$16,935,000
Shares Out
27,074,516
Trailing EPS
$-0.91
Book Value
$6.68
ROE
-13.1%
ROA
-6.1%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 348,668,000 -30,207,000 -22,747,000 298,625,000 106,394,000 -11,216,000
Dec 2024 335,705,000 -42,516,000 -35,888,000 296,185,000 122,325,000 5,914,000
Dec 2023 315,660,000 -76,492,000 -102,449,000 326,194,000 121,382,000 -3,234,000
Dec 2022 377,241,000 -33,082,000 -83,772,000 405,041,000 107,635,000 -37,532,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.26

Peers — same industry

TickerNameMarket CapLastDaily %
NYXH Nyxoah SA $171.12M $1.71
APYX Apyx Medical Corp $184.44M $4.38
STXS Stereotaxis, Inc. $166.15M $1.70
LUCD Lucid Diagnostics Inc. $190.77M $1.00
EMBC Embecta Corp. $192.22M $3.24

News headlines (Yahoo Finance, 1h cache)

Inogen Announces the Appointment of Andy Reding as Chief Operating Officer
2026-07-01 20:05 · Yahoo
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
2026-06-25 14:12 · Yahoo
How The Inogen (INGN) Story Is Shifting With New Targets And Execution Questions
2026-05-11 00:18 · Yahoo
INGN Stock Dips on Q1 Earnings Miss, Sales Up Y/Y, Gross Margin Improves
2026-05-08 14:41 · Yahoo
Inogen, Inc. Q1 2026 Earnings Call Summary
2026-05-08 12:30 · Yahoo
Inogen Q1 Earnings Call Highlights
2026-05-08 04:06 · Yahoo
Inogen (INGN) Reports Q1 Loss, Beats Revenue Estimates
2026-05-07 23:05 · Yahoo
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
2026-05-05 13:15 · Yahoo
We're Not Very Worried About Inogen's (NASDAQ:INGN) Cash Burn Rate
2026-04-28 10:28 · Yahoo
Beta Bionics, Inc. (BBNX) Reports Q1 Loss, Misses Revenue Estimates
2026-04-21 21:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.